Page last updated: 2024-11-10

ici 154129

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ICI 154129: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035055
SCHEMBL ID4405821
MeSH IDM0110933

Synonyms (24)

Synonym
ici-154129
n,n-bis(allyl)-tyrosyl-glycyl-glycyl-psi-methylthio-phenylalanyl-leucine
l-leucine, n,n-di-2-propenyl-l-tyrosylglycyl-(alphas)-alpha-((2-aminoethyl)thio)benzenepropanoyl-
ici 154129
n,n-di-2-propenyl-l-tyrosylglycyl-(alphas)-alpha-((2-aminoethyl)thio)benzenepropanoyl-l-leucine
m 154,129
n,n-bis(allyl)-tyr-gly-gly-psi-methylthio-phe-leu
glycinamide, n,n-di-2-propenyl-l-tyrosyl-n-(2-((2-((1-carboxy-3-methylbutyl)amino)-2-oxo-1-(phenylmethyl)ethyl)thio)ethyl)-, (s-(r*,r*))-
m-154,129
(2s)-2-[[(2s)-2-[2-[[2-[[(2s)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]ethylsulfanyl]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
83420-94-4
unii-97bue7nr2m
97bue7nr2m ,
ici 154,129
l-leucine, n,n-di-2-propen-1-yl-l-tyrosylglycyl-(.alpha.s)-.alpha.-((2-aminoethyl)thio)benzenepropanoyl-
m-154129
DTXSID00232349
SCHEMBL4405821
AKOS024458661
((s)-2-((2-(2-((s)-2-(diallylamino)-3-(4-hydroxyphenyl)propanamido)acetamido)ethyl)thio)-3-phenylpropanoyl)-l-leucine
ici154129;ici 154129;m 154129;m154129;m-154129
Q27272001
HY-101233
CS-0021020

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A dose-response study demonstrated that the maximum growth hormone release was obtained with 10 micrograms/kg while higher doses were less or not effective."( The growth hormone secretory response to fentanyl in rat: an involvement of mu type receptors.
Buydens, P; Finné, E; Govaerts, J; Matton, A; Vanhaelst, L, 1990
)
0.28
" ICI 154,129 was proconvulsant in the mouse picrotoxin potentiation test; the dose-response curve had a low ceiling and was biphasic."( In vivo studies with ICI 154,129, a putative delta receptor antagonist.
Cowan, A; Gmerek, DE,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (73.33)18.7374
1990's18 (24.00)18.2507
2000's0 (0.00)29.6817
2010's1 (1.33)24.3611
2020's1 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.13 (24.57)
Research Supply Index4.43 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.22%)5.53%
Reviews1 (1.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other80 (97.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]